Display options
Cite
Nagel G, Peter RS, Klotz E, et al. Bone mineral density and breast cancer risk: Results from the Vorarlberg Health Monitoring & Prevention Program and meta-analysis. Bone Rep. 2017;7:83-89doi: 10.1016/j.bonr.2017.09.004.
Nagel, G., Peter, R. S., Klotz, E., Brozek, W., & Concin, H. (2017). Bone mineral density and breast cancer risk: Results from the Vorarlberg Health Monitoring & Prevention Program and meta-analysis. Bone reports, 783-89. https://doi.org/10.1016/j.bonr.2017.09.004
Nagel, G, et al. "Bone mineral density and breast cancer risk: Results from the Vorarlberg Health Monitoring & Prevention Program and meta-analysis." Bone reports vol. 7 (2017): 83-89. doi: https://doi.org/10.1016/j.bonr.2017.09.004
Nagel G, Peter RS, Klotz E, Brozek W, Concin H. Bone mineral density and breast cancer risk: Results from the Vorarlberg Health Monitoring & Prevention Program and meta-analysis. Bone Rep. 2017 Sep 21;7:83-89. doi: 10.1016/j.bonr.2017.09.004. eCollection 2017 Dec. PMID: 29018837; PMCID: PMC5626919.
Copy Download .nbib Format: NLM
Share it on

Bone Rep. 2017 Sep 21;7:83-89. doi: 10.1016/j.bonr.2017.09.004. eCollection 2017 Dec.

Bone mineral density and breast cancer risk: Results from the Vorarlberg Health Monitoring & Prevention Program and meta-analysis.

Bone reports

G Nagel, R S Peter, E Klotz, W Brozek, H Concin

Affiliations

  1. Institute of Epidemiology and Medical Biometry, Ulm University, Helmholtzstrasse 22, 89081 Ulm, Germany.
  2. Agency for Preventive and Social Medicine, Rheinstrasse 61, 6900 Bregenz, Austria.
  3. Ludwig Boltzmann Institute of Osteology at the Hanusch Hospital of the Vienna Health Insurance Fund (WGKK) and Trauma Center Meidling of the Austrian Workers' Compensation Board (AUVA), 1st Medical Department, Hanusch Hospital, Vienna, Austria.

PMID: 29018837 PMCID: PMC5626919 DOI: 10.1016/j.bonr.2017.09.004

Abstract

We investigated the association between bone mineral density (BMD) and breast cancer risk in a large prospective cohort and quantified the evidence in a meta-analysis of prospective studies. Baseline BMD has been measured by dual energy X-ray absorptiometry (DXA, N = 1418). Data on medication and lifestyle has been collected by questionnaire. Cox proportional Hazards models were applied to calculate Hazard Ratios for breast cancer. In addition, a meta-analysis on categorical and dose-response values including the current results has been performed applying random-effects models. During mean follow-up of 16.3 (SD 3.3) years of 1380 women (mean age 55.5 ± 6.3 years), 52 cases of invasive breast cancer were identified. We found no statistically significant association of BMD with breast cancer risk (per one z-score increase, HR 0.91, 95% CI 0.67-1.23). In the meta-analysis, however, breast cancer risk increased by 15% and 16% per 0.1 g/m

Keywords: Bone mineral density; Breast cancer; Epidemiology; Meta-analysis; VHM&PP

References

  1. Breast. 2001 Aug;10(4):313-7 - PubMed
  2. Breast Cancer Res. 2007;9(1):R6 - PubMed
  3. Bone. 2003 Mar;32(3):211-6 - PubMed
  4. Climacteric. 2011 Jun;14 (3):352-61 - PubMed
  5. Maturitas. 2002 Apr 15;41 Suppl 1:S9-12 - PubMed
  6. Cancer. 2008 Sep 1;113(5):907-15 - PubMed
  7. J Natl Cancer Inst. 2005 Mar 2;97(5):368-74 - PubMed
  8. Nat Rev Rheumatol. 2010 Feb;6(2):99-105 - PubMed
  9. J Clin Endocrinol Metab. 2010 Aug;95(8):3569-77 - PubMed
  10. Cancer Causes Control. 2001 Apr;12(3):213-22 - PubMed
  11. BMC Cancer. 2002 Sep 12;2(1):22 - PubMed
  12. Arch Osteoporos. 2013;8:136 - PubMed
  13. Breast Cancer Res. 2014 Sep 28;16(5):446 - PubMed
  14. Steroids. 2015 Jul;99(Pt A):61-6 - PubMed
  15. Breast Cancer Res Treat. 2013 Feb;138(1):261-71 - PubMed
  16. Maturitas. 2000 Jul 31;36(1):27-34 - PubMed
  17. Breast Cancer Res Treat. 2007 Apr;102(2):181-8 - PubMed
  18. Ann Epidemiol. 2014 Mar;24(3):222-7 - PubMed
  19. BMJ. 2003 Sep 6;327(7414):557-60 - PubMed
  20. Nat Rev Cancer. 2014 May;14 (5):342-57 - PubMed
  21. Breast Cancer Res Treat. 2011 Apr;126(3):679-86 - PubMed
  22. Endocr Relat Cancer. 2005 Dec;12(4):1071-82 - PubMed
  23. Eur J Cancer. 2015 Jun;51(9):1164-87 - PubMed
  24. PLoS One. 2013 Aug 05;8(8):e70980 - PubMed
  25. JAMA. 1996 Nov 6;276(17):1404-8 - PubMed
  26. J Natl Cancer Inst. 2001 Jun 20;93(12):930-6 - PubMed
  27. Maturitas. 2007 Mar 20;56(3):312-21 - PubMed
  28. Osteoporos Int. 2006;17(8):1196-201 - PubMed
  29. Osteoporos Int. 2005 Dec;16(12):1627-32 - PubMed
  30. Eur J Epidemiol. 2004;19(8):785-92 - PubMed
  31. Am J Epidemiol. 1998 Jul 1;148(1):22-9 - PubMed
  32. Bone. 2010 Jan;46(1):244-7 - PubMed
  33. J Clin Epidemiol. 2001 Apr;54(4):417-22 - PubMed
  34. Environ Health Perspect. 1997 Apr;105 Suppl 3:593-9 - PubMed
  35. Osteoporos Int. 2008 Oct;19(10):1497-504 - PubMed
  36. Trends Endocrinol Metab. 2012 Nov;23(11):576-81 - PubMed
  37. N Engl J Med. 1997 Feb 27;336(9):611-7 - PubMed
  38. Endocr Relat Cancer. 2006 Jun;13(2):593-605 - PubMed
  39. Curr Med Res Opin. 2008 Mar;24(3):807-13 - PubMed

Publication Types